Status:
WITHDRAWN
PRIMADOS Study:A Study of Avastin (Bevacizumab) Plus Docetaxel for First Line Treatment of Patients With Metastatic Breast Cancer
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Breast Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
This single arm study will assess the efficacy and safety of first line combination treatment with Avastin + docetaxel in patients with HER2 negative metastatic breast cancer.Patients will receive Ava...
Eligibility Criteria
Inclusion
- male and female patients, \>=18 years of age;
- stage IV, HER2 negative metastatic breast cancer;
- candidate for taxane-based therapy;
- ECOG performance status 0-2.
Exclusion
- prior chemotherapy for metastatic breast cancer;
- concomitant primary malignant disease, except for adequately treated cervical cancer in situ, or basal or squamous cell skin cancer within last 5 years;
- suspicion of CNS metastasis;
- clinically significant cardiovascular disease.
Key Trial Info
Start Date :
January 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2013
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00774241
Start Date
January 1 2010
End Date
November 1 2013
Last Update
November 2 2016
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.